News & Events:JNJ

F-Star Therapeutics Inc (FSTX): * F-STAR THERAPEUTICS ANNOUNCES LICENSE AGREEMENT WITH JANSSEN TO DEVELOP AND COMMERCIALIZE MULTIPLE NEXT GENERATION BISPECIFIC ANTIBODY THERAPEUTICS. * F-Star Therapeutics Inc (FSTX) - JANSSEN WILL BE RESPONSIBLE FOR ALL RESEARCH, DEVELOPMENT, AND COMMERCIALIZATION ACTIVITIES UNDER AGREEMENT.

The United States has administered 409,438,987 doses of COVID-19 vaccines in the country as of Tuesday morning and distributed 495,844,635 doses, the U.S. Centers for Disease Control and Prevention said. Those figures are up from the 408,797,942 vaccine doses the CDC said had gone into arms by Oct. 18 out of 494,655,075 doses delivered.

* All three major U.S. stock indexes end higher. * Oil, gold futures rise. * Dollar stumbles. By Caroline Valetkevitch. Stock indexes around the world jumped on Tuesday as U.S. technology shares extended recent gains and earnings reports were upbeat, while the 10-year U.S. Treasury yield rose to its highest in more than four months.

By Shreyashi Sanyal and Sinéad Carew. U.S. stock indexes closed higher on Tuesday with the biggest boosts from the technology and healthcare sectors as investors appeared to bet on solid quarterly reports even as some worried that it was too early to celebrate. In its fifth straight session of gains, the benchmark S&P 500 index neared its early September record high.

* J&J raises 2021 profit forecast after Q3 earnings beat. * Insurer Travelers rises after beating profit estimates. * Walmart (WMT) up on entering GS 'conviction list' * P&G falls after warning on higher supply chain costs. * Indexes up: Dow 0.31%, S&P 0.53%, Nasdaq 0.54% By Shreyashi Sanyal and Sinéad Carew.

* Housing starts fall 1.6% in September; August revised down. * Single-family starts unchanged; multifamily drop 5.0% * Building permits tumble 7.7%; single family decrease 0.9% By Lucia Mutikani.

* J&J raises 2021 profit forecast after Q3 earnings beat. * Insurer Travelers rises after beating profit estimates. * Walmart (WMT) up on entering GS 'conviction list' * P&G falls after warning on higher supply chain costs. * Indexes up: Dow 0.31%, S&P 0.39%, Nasdaq 0.44% By Shreyashi Sanyal.

* J&J raises 2021 profit forecast after Q3 earnings beat. * Walmart (WMT) up after entering GS 'conviction list' * P&G falls on higher supply chain costs warning. * Futures up: Dow 0.42%, S&P 0.42%, Nasdaq 0.34% By Shreyashi Sanyal.

* J&J raises 2021 profit forecast after Q3 earnings beat. * Walmart (WMT) rises on entering GS "conviction list" * Futures up: Dow 0.42%, S&P 0.45%, Nasdaq 0.34% By Shreyashi Sanyal. Oct 19 - U.S. stock index futures rose on Tuesday as an upbeat profit forecast from Johnson & Johnson (JNJ) added to the positive momentum in corporate earnings generated by big banks last week.

Johnson & Johnson (JNJ) on Tuesday raised its adjusted profit forecast for 2021, even as it stuck to its outlook of $2.5 billion in sales from its COVID-19 vaccine this year. The company raised its annual adjusted earnings forecast to between $9.77 per share and $9.82 per share, from its prior estimates of $9.60 to $9.70 per share.

Johnson & Johnson (JNJ): * REPORTS Q3 2021 RESULTS. * Q3 EARNINGS PER SHARE $1.37. * Q3 SALES $23.3 BILLION VERSUS REFINITIV IBES ESTIMATE OF $23.78 BILLION. * Q3 ADJUSTED EARNINGS PER SHARE $2.60. * Q3 EARNINGS PER SHARE ESTIMATE $2.36 -- REFINITIV IBES DATA. * J&J - COMPANY INCREASING 2021 FULL-YEAR GUIDANCE. * J&J - QTRLY WORLDWIDE COVID-19 VACCINE SALES $502 MILLION.

-Johnson & Johnson (JNJ) on Tuesday reported lower-than- expected quarterly revenue after sales of its COVID-19 vaccine missed Wall Street estimates following a string of production setbacks.

Johnson & Johnson (JNJ) on Tuesday maintained its 2021 sales forecast for its COVID-19 vaccine at $2.5 billion and reported $502 million in sales of the single-dose shot in the third quarter.

NEW BRUNSWICK, N.J., Oct. 19, 2021  Johnson & Johnson (JNJ) today announced results for third-quarter 2021.  .  . THIRD QUARTER 2021 SEGMENT COMMENTARY: Consumer HealthConsumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, increased 5.7%* primarily driven by over-the-counter products.

A look at the day ahead from Sujata Rao. It took two weeks for UK money markets to go from expecting no interest rate rises this year to betting on a cumulative 35 basis-point moves in November and December. Besides Britain, some are placing bets on a September 2022 Fed rate hike; a month ago, no move was predicted before 2023. So, is it justified?

A look at the day ahead from Sujata Rao It took two weeks for UK money markets to go from expecting no interest rate rises this year to betting on a cumulative 35 basis-point moves in November and December. Besides Britain, some are placing bets on a September 2022 Fed rate hike; a month ago, no move was predicted before 2023. So, is it justified?

The following are the top stories in the Wall Street Journal. - The U.S. Food and Drug Administration is moving to soon allow people to receive booster shots that are different from their first COVID-19 vaccine doses, people familiar with the matter said. https://on.wsj.com/30G1yID.

The U.S. Food and Drug Administration is planning to allow mixing and matching of booster shots of COVID-19 vaccines in the country, the New York Times reported on Monday, citing people familiar with the agency's plans.

The United States has administered 408,797,942 doses of COVID-19 vaccines in the country as of Monday morning and distributed 494,655,075 doses, the U.S. Centers for Disease Control and Prevention said. The figures are up from the 408,265,959 vaccine doses the CDC said had gone into arms by Oct. 17.

* Consumer discretionary sector leads S&P gainers. * Utilities lead S&P sector losers. * Disney (DIS) slips after Barclays downgrades to 'equal weight' * Dow down 0.1%, S&P up 0.34%, Nasdaq up 0.84% By Devik Jain, Shreyashi Sanyal and Sinéad Carew.